BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25189344)

  • 1. Relative risk of myelodysplastic syndromes in patients with autoimmune disorders in the General Practice Research Database.
    Wilson AB; Neogi T; Prout M; Jick S
    Cancer Epidemiol; 2014 Oct; 38(5):544-9. PubMed ID: 25189344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The myelodysplastic syndrome and autoimmunity].
    Laursen SB; Nielsen MØ; Hasselbalch HC
    Ugeskr Laeger; 2009 Sep; 171(37):2639-42. PubMed ID: 19758507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of myelodysplastic syndrome and acute myeloid leukemia post radiation treatment for breast cancer: a population-based study.
    Kaplan H; Malmgren J; De Roos AJ
    Breast Cancer Res Treat; 2013 Feb; 137(3):863-7. PubMed ID: 23274844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic immune stimulation might act as a trigger for the development of acute myeloid leukemia or myelodysplastic syndromes.
    Kristinsson SY; Björkholm M; Hultcrantz M; Derolf ÅR; Landgren O; Goldin LR
    J Clin Oncol; 2011 Jul; 29(21):2897-903. PubMed ID: 21690473
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune diseases and myelodysplastic syndromes.
    Komrokji RS; Kulasekararaj A; Al Ali NH; Kordasti S; Bart-Smith E; Craig BM; Padron E; Zhang L; Lancet JE; Pinilla-Ibarz J; List AF; Mufti GJ; Epling-Burnette PK
    Am J Hematol; 2016 May; 91(5):E280-3. PubMed ID: 26875020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The relationship between myelodysplastic syndromes and autoimmune disorders.
    Zhao S; Mao H; Wang H; Yu J
    Zhonghua Xue Ye Xue Za Zhi; 2002 Jun; 23(6):311-3. PubMed ID: 12411063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and risk factors for infections in myelodysplastic syndromes.
    Sullivan LR; Sekeres MA; Shrestha NK; Maciejewski JP; Tiu RV; Butler R; Mossad SB
    Transpl Infect Dis; 2013 Dec; 15(6):652-7. PubMed ID: 24010918
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autoimmune disorders are common in myelodysplastic syndrome patients and confer an adverse impact on outcomes.
    Montoro J; Gallur L; Merchán B; Molero A; Roldán E; Martínez-Valle F; Villacampa G; Navarrete M; Ortega M; Castellví J; Saumell S; Bobillo S; Bosch F; Valcárcel D
    Ann Hematol; 2018 Aug; 97(8):1349-1356. PubMed ID: 29572561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case-control study of risk factors of myelodysplastic syndromes according to World Health Organization classification in a Chinese population.
    Lv L; Lin G; Gao X; Wu C; Dai J; Yang Y; Zou H; Sun H; Gu M; Chen X; Fu H; Bao L
    Am J Hematol; 2011 Feb; 86(2):163-9. PubMed ID: 21264898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database.
    Shukron O; Vainstein V; Kündgen A; Germing U; Agur Z
    Am J Hematol; 2012 Sep; 87(9):853-60. PubMed ID: 22674538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risks of myeloid malignancies in patients with autoimmune conditions.
    Anderson LA; Pfeiffer RM; Landgren O; Gadalla S; Berndt SI; Engels EA
    Br J Cancer; 2009 Mar; 100(5):822-8. PubMed ID: 19259097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Venous thromboembolism during systemic inflammatory and autoimmune diseases associated with myelodysplastic syndromes, chronic myelomonocytic leukaemia and myelodysplastic/myeloproliferative neoplasms: a French multicentre retrospective case-control study.
    Péan de Ponfilly-Sotier M; Jachiet V; Benhamou Y; Lahuna C; De Renzis B; Kottler D; Voillat L; Dimicoli-Salazar S; Banos A; Chauveheid MP; Alexandra JF; Grignano E; Liferman F; Laborde M; Broner J; Michel M; Lambotte O; Laribi K; Venon MD; Dussol B; Martis N; Thepot S; Park S; Couret D; Roux-Sauvat M; Terriou L; Hachulla E; Bally C; Galland J; Allain JS; Parcelier A; Peterlin P; Cohen-Bittan J; Regent A; Ackermann F; Le Guen J; Algrin C; Charles P; Daguindau E; Puechal X; Dunogue B; Blanchard-Delaunay C; Beyne-Rauzy O; Grobost V; Schmidt J; Le Gallou T; Dubos-Lascu G; Sonet A; Denis G; Roy-Peaud F; Fenaux P; Adès L; Fain O; Mekinian A;
    Clin Exp Rheumatol; 2022 Jul; 40(7):1336-1342. PubMed ID: 35579092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk for developing myelodysplastic syndromes in prostate cancer patients definitively treated with radiation.
    Mukherjee S; Reddy CA; Ciezki JP; Abdel-Wahab M; Tiu RV; Copelan E; Advani AA; Saunthararajah Y; Paulic K; Hobson S; Maciejewski JP; Bolwell BJ; Kalaycio M; Dreicer R; Klein EA; Sekeres MA
    J Natl Cancer Inst; 2014 Mar; 106(3):djt462. PubMed ID: 24577815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personal history of autoimmune disease and other medical conditions and risk of myelodysplastic syndromes.
    Linabery AM; Roesler MA; Richardson M; Warlick ED; Nguyen PL; Cioc AM; Poynter JN
    Cancer Epidemiol; 2022 Feb; 76():102090. PubMed ID: 34995873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for de novo and therapy-related myelodysplastic syndromes (MDS).
    Yarosh R; Roesler MA; Murray T; Cioc A; Hirsch B; Nguyen P; Warlick E; Poynter JN
    Cancer Causes Control; 2021 Mar; 32(3):241-250. PubMed ID: 33392905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and survival analysis in primary myelodysplastic syndromes patients with immunological abnormalities].
    Li B; Xu ZF; Cui R; Chen YD; Su T; Zhang TJ; Fang LW; Zhang HL; Qin TJ; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Jul; 33(7):527-31. PubMed ID: 22967411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is thyroid autoimmunity a risk factor for developing primary myelodysplastic syndrome?
    Dalamaga M; Lekka A; Karmaniolas K; Stathopoulou E; Dionyssiou-Asteriou A
    Cancer Causes Control; 2008 May; 19(4):371-8. PubMed ID: 18064534
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression of differentiation antigens on bone marrow myeloid cells of the patients with myelodysplastic syndromes and its clinical significances].
    Li LJ; Fu R; Wang HQ; Yue LZ; Liu H; Wang J; Wang HL; Ruan EB; Qu W; Liang Y; Wang GJ; Wang XM; Liu H; Song J; Wu YH; Xing LM; Guan J; Shao ZH
    Zhonghua Yi Xue Za Zhi; 2010 Mar; 90(10):672-7. PubMed ID: 20450725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.